Up‑regulation of lncRNA PXN-AS1-L is associated with unfavorable prognosis in patients suffering from glioma

F. Shang, S.-W. Du, X.-L. Ma

Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Xicheng, Beijing, China. senior_ma@126.com

---

• Oncology

OBJECTIVE: Growing evidence has proved that long noncoding RNAs (lncRNAs) act as novel regulators in the progression of various tumors by modulating miRNAs and tumor-related genes. However, the potential function of lncRNA PXN-AS1-L (PXN-AS1-L) in glioma remains unknown. Hence, we aimed to determine whether PXN-AS1-L was dysregulated in glioma and further preliminarily explored its prognostic value in glioma patients.
PATIENTS AND METHODS: RT-PCR was used for the assessment of PXN-AS1-L levels in glioma tissue and matched normal tissues from our hospital. Chi-square test was applied to explore the possible association between PXN-AS1-L expressions and clinical factors. Kaplan-Meier survival analysis was carried out to determine the influence of PXN-AS1-L expressions on the survival rate of glioma patients. Survival data were further evaluated through univariate and multivariate analyses.
RESULTS: PXN-AS1-L levels were differentially upregulated in glioma specimens compared with paired non-tumor specimens. Higher levels of PXN-AS1-L in glioma were observed to be positively associated with WHO grade (p = 0.019), KPS (p = 0.008)and tumor recurrence (p = 0.019). Survival assays revealed that glioma patients with higher PXN-AS1-L expressions had worse overall survival rates. In multivariate analysis, upregulation of PXN-AS1-L expressions (Risk ratio = 2.663, 1.218-4.532, p = 0.014) in glioma tissues was confirmed to be an independent prognostic factor of overall survival in patients.
CONCLUSIONS: We firstly suggested that PXN-AS1-L was overexpressed in glioma, and could be used as a novel marker of unfavorable outcome in glioma patients.

Free PDF Download